Added to YB: 2025-11-12
Pitch date: 2025-11-06
STVN [neutral]
Stevanato Group S.p.A.
-14.71%
current return
Author Info
Best Anchor Stocks shares deep research on companies with long-term potential aThe Bear Cavend lower-than-average volatility. Sign up for the newsletter.
Company Info
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Market Cap
$5.2B
Pitch Price
$24.41
Price Target
N/A
Dividend
0.28%
EV/EBITDA
20.28
P/E
37.31
EV/Sales
4.72
Sector
Life Sciences Tools and Services
Category
growth
This is the thesis: Stevanato's Q3
STVN (earnings): Q3 showed 11% revenue growth (constant currency) with BDS +17% offsetting engineering -19%. BDS margins expanded 400bp to 60% incremental gross margin despite headwinds. HVS grew 47% to 55% of BDS revenue, driving margin expansion. Op profit +25% despite engineering losses. 2026 outlook strong.
Read full article (4 min)